ST Pharm reports Phase 2a trial shows HIV-1 drug candidate STP0404 cuts viral load vs placebo

• ST Pharm received the final clinical study report on Oct. 3, 2026 for its U.S. Phase 2a HIV-1 drug candidate STP0404.
• Results were previously disclosed as topline data on July 14, 2026; fuller findings are slated for a future international medical meeting.
• The trial showed antiviral activity versus placebo, with a generally favorable safety and tolerability profile over the short dosing period.
• Management plans to use the data to shape next-step development aimed at positioning STP0404 as a new option in standard HIV care.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ST Pharm Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261006900277), on October 06, 2026, and is solely responsible for the information contained therein.